Troya Therapeutics ApS: Financial statements 2024
CVR: 44032589
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Troya Therapeutics ApS (CVR 44032589) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -991,416 and a net result of DKK -1,440,941. Equity in the 2024 report amounted to DKK -1,760,158.
- Gross Profit
- DKK -991,416
- Profit/Loss
- DKK -1,440,941
- Equity
- DKK -1,760,158
- Total Assets
- DKK 3,943,978
- Employees
- 0
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
Troya Therapeutics ApS has published its interim report for the period April 24, 2023 to December 31, 2023.
About Troya Therapeutics ApS
Troya Therapeutics ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2023. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Austin Wayne Boesch. The board consists of Ulrik Bjerl Nielsen (chair), Christian Grøndahl and Sean Dean Lykke Harwood. The company's owners include Ulrik Bjerl Nielsen, Seandean Lykke Harwood Holding ApS and EnghildThøgersen Holding ApS. The company has 6 employees (2026). In 2025, the company reported a gross profit of DKK -2,381,639 and a net result of DKK -4,638,321 compared with DKK -1,440,941 the year before. Equity in the 2025 report amounted to DKK -6,398,479.